References
- Canadian Liver Foundation. Liver Cancer and tumors (2017). https://www.liver.ca/patients-caregivers/liver-diseases/liver-cancer/
- Canadian Cancer Society. Treatments for stage 0 liver cancer (2019). https://cancer.ca/en/cancer-information/cancer-types/liver/treatment/stage-0
- Canadian Cancer Society. Treatments for stage A liver cancer (2019). https://cancer.ca/en/cancer-information/cancer-types/liver/treatment/stage-a
- Canadian Cancer Society. Treatments for stage C liver cancer (2019). https://cancer.ca/en/cancer-information/cancer-types/liver/treatment/stage-c
- Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
- Bayer. A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (2014). https://www.clinicaltrials.gov/ct2/show/results/NCT00105443?view=results
- Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase III non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).
- Eisai Limited, Merck Sharp & Dohme LLC. A multicenter, randomized, open-label, Phase III trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma (2022). https://clinicaltrials.gov/ct2/show/NCT01761266
- Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 82(20), 1894–1905 (2020).
- Abou-Alfa GK, Lau G, Kudo M et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1(8) (2022).
- CADTH. Tecentriq & Avastin for Hepatocellular Carcinoma (2020). www.cadth.ca/tecentriq-avastin-hepatocellular-carcinoma-details
- Samawi HH, Sim H, Chan KK et al. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med. 7(7), 2816–2825 (2018).
- O’Sullivan DM, Boyne DJ, Syed I et al. Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. Can. Liver J. 5(4), 476–492 (2022).
- Hanumanthappa N, Cho BJ, McKay A et al. Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba. Can. Liver J. 3(2), 194–202 (2020).
- Thein HH, Isaranuwatchai W, Campitelli MA et al. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 58(4), 1375–1384 (2013).
- Statistics Canada. Census Program (2021). www12.statcan.gc.ca/census-recensement/index-eng.cfm
- Ministry of Health. Medical Services Commission Payment Schedule (2021). www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment-schedule-may-2021.pdf
- Thein HH, Khoo E, Campitelli MA et al. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open. 3(2), E208–E216 (2015).
- Cancer Research UK. Survival Liver cancer (2022). https://www.cancerresearchuk.org/about-cancer/liver-cancer/survival
- Burton A, Tataru D, Driver RJ et al. Primary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep. 3(2), 100232 (2021).
- Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J. Hepatol. 66(3), 537–544 (2016).
- Hong TP, Gow PJ, Fink M et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med. J. Aust. 209(8), 348–354 (2018).
- Exchange Rates UK. US Dollar to Canadian Dollar Spot Exchange Rates for 2010 (2023). www.exchangerates.org.uk/USD-CAD-spot-exchange-rates-history-2010.html
- Bank of Canada. Inflation Calculator (2023). www.bankofcanada.ca/rates/related/inflation-calculator/